MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · IEX Real-Time Price · USD
4.400
-0.230 (-4.97%)
Jul 19, 2024, 4:00 PM EDT - Market closed
MaxCyte Employees
MaxCyte had 143 employees as of December 31, 2023. The number of employees increased by 18 or 14.40% compared to the previous year.
Employees
143
Change (1Y)
18
Growth (1Y)
14.40%
Revenue / Employee
$308,068
Profits / Employee
-$255,716
Market Cap
459.99M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Enhabit | 10,800 |
Bioventus | 970 |
Pacific Biosciences of California | 796 |
Voyager Therapeutics | 162 |
Absci | 155 |
EyePoint Pharmaceuticals | 121 |
Theravance Biopharma | 99 |
Third Harmonic Bio | 30 |
MXCT News
- 12 days ago - MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 - GlobeNewsWire
- 7 weeks ago - MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference - GlobeNewsWire
- 2 months ago - MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development - GlobeNewsWire
- 2 months ago - MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance - GlobeNewsWire
- 3 months ago - MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 3 months ago - MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) - GlobeNewsWire
- 4 months ago - MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance - GlobeNewsWire
- 4 months ago - MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results - GlobeNewsWire